H.C. Wainwright raised the firm’s price target on Travere Therapeutics (TVTX) to $57 from $47 and keeps a Buy rating on the shares post the Q1 report. The company is “heading in the trajectory of continued de-risking commercial story,” the analyst tells investors in a research note. The firm views the quarter as supportive of the broader Filspari growth story.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics Bets Big on FILSPARI Momentum
- Travere Therapeutics reports Q1 EPS 5c, consensus (5c)
- Travere Therapeutics options imply 5.7% move in share price post-earnings
- Travere Therapeutics, Inc. (TVTX) Q1 Earnings Cheat Sheet
- Travere Therapeutics price target raised to $56 from $54 at Guggenheim